Parkinson's Disease

✍ Scribed by Manuchair Ebadi, Ronald F. Pfeiffer

• Year: 2004
• Tongue: English
• Leaves: 1718
• Edition: 1
• Category: Library

✦ Synopsis

Recent research is leading to an ever-increasing range of investigative approaches whose aim is to achieve effective neuroprotective or neurorestorative treatment for individuals affected by Parkinson’s disease. New directions under investigation reach beyond traditional pharmacological approaches to venture into innovative surgical methods, gene therapy, stem cell therapy, and neurotransplantation. In this comprehensive volume, leading medical authorities provide state-of-the-art information on all aspects of Parkinson’s disease. They cover the historical background, neuropathological and neurophysiological characteristics, epidemiological aspects, clinical features, current treatment approaches, and potential therapeutic methods. Novel models are included to simplify more complex concepts.

✦ Table of Contents

Book Cover......Page 1
Half-Title......Page 2
Title......Page 4
Copyright......Page 5
Dedication......Page 6
In Memoriam......Page 7
Preface......Page 9
Acknowledgments......Page 13
About the Editors......Page 15
Contributors......Page 18
Table of Contents......Page 35
1. James Parkinson......Page 43
2. Paralysis Agitans—Refining the Diagnosis and Treatment......Page 58
3. The Role of Dopamine in Parkinson’s Disease: A Historical Review......Page 74
4. Parkinson’s Disease: Where Are We?......Page 82
5. Epidemiology of Parkinson’s Disease: An Overview......Page 101
6. Environmental Toxins and Parkinson’s Disease......Page 119
7. Rural Environment and Parkinson’s Disease......Page 138
8. Industrial and Occupational Exposures and Parkinson’s Disease......Page 153
9. Tetrahydroisoquinolines and Parkinson’s Disease......Page 164
10. Xenobiotic Metabolism and Idiopathic Parkinson’s Disease......Page 189
11. Progressive Neurodegeneration in the Chronic MPTP/Probenecid Model of Parkinson’s Disease......Page 208
12. Alpha-Synuclein and Parkinson’s Disease......Page 219
13. Parkin and Its Role in Parkinson’s Disease......Page 236
14. Heredofamilial Parkinsonism......Page 250
15. Other Mutations: Their Role in Parkinson’s Disease......Page 281
16. Classical Motor Features of Parkinson’s Disease......Page 300
17. Clinical Evaluation and Treatment of Gait Disorders in Parkinson’s Disease......Page 317
18. Sensory Symptoms and Sensorimotor Distortion in Parkinson’s Disease......Page 328
19. Pain in Parkinson’s Disease......Page 340
20. Fatigue: A Common Comorbidity in Parkinson’s Disease......Page 355
21. Sleep Disorders in Parkinson’s Disease......Page 367
22. Visual Function in Parkinson’s Disease......Page 386
23. Visuocognitive Dysfunctions in Parkinson’s Disease......Page 399
24. Olfactory Dysfunction in Parkinson’s Disease and Parkinsonian Syndromes......Page 418
25. Gastrointestinal Dysfunction in Parkinson’s Disease......Page 433
26. Urinary Dysfunction in Parkinson’s Disease......Page 458
27. Sexual Dysfunction......Page 476
28. Cardiovascular Autonomic Dysfunction in Parkinson’s Disease and Parkinsonian Syndromes......Page 488
29. Disorders of Thermoregulation in Parkinson’s Disease......Page 529
30. Respiratory Dysfunction......Page 535
31. Depression in Parkinson’s Disease......Page 544
32. Anxiety and Parkinson’s Disease......Page 559
33. Dementia in Parkinson’s Disease......Page 571
34. Animal Models of Basal Ganglia Injury and Degeneration and Their Application to Parkinson’s Disease Research......Page 602
35. The Neuropathology of Parkinson’s Disease and Other Parkinsonian Disorders......Page 653
36. Pathophysiology of the Motor Disorder......Page 680
37. MPTP Disrupts Dopamine Receptors and Dopamine Transporters......Page 701
38. Pathophysiology of Parkinson’s Disease, Neurochemical Pathology: Other Neurotransmitters.......Page 718
39. Metallothionein Isoforms Attenuate Peroxynitrite-Induced Oxidative Stress in Parkinson’s Disease......Page 773
40. Excitotoxicity in Parkinson’s Disease......Page 808
41. Inflammation......Page 829
42. Cell Death in Parkinson’s Disease......Page 853
43. Weaver Mutant Mouse in Progression of Neurodegeneration in Parkinson’s Disease......Page 874
44. Differential Diagnosis of Parkinson’s Disease......Page 905
45. Diagnostic Criteria for Parkinson’s Disease......Page 925
46. Neuroleptic-Induced Movement Disorders......Page 940
47. The Placebo Effect in Parkinson’s Disease......Page 1008
48. Dopamine Transporter Imaging Using SPECT in Parkinson’s Disease......Page 1020
49. MR Imaging of Parkinsonism......Page 1036
50. Clinical Batteries......Page 1059
51. Rating Scales......Page 1072
52. Treatment of Parkinson’s Disease with Anticholinergic Medications......Page 1095
53. Amantadine......Page 1107
54. The Role of MAO-B Inhibitors in the Treatment of Parkinson’s Disease......Page 1116
55. Catechol-O-Methyltransferase Inhibitors in the Treatment of Parkinson’s Disease......Page 1137
56. Symptomatic Treatment of Parkinson’s Disease: Levodopa......Page 1149
57. Dopamine Agonists in Parkinson’s Disease......Page 1176
58. Parkinson’s Disease: Surgical Treatment-Stereotactic Procedures......Page 1200
59. Neurotransplantation in Parkinson’s Disease......Page 1235
60. The Role of Physical Therapy in Management of Parkinson’s Disease......Page 1250
61. Swallowing Function in Parkinson’s Disease......Page 1262
62. Restorative and Psychosocial Occupational Therapy in Parkinson’s Disease......Page 1274
63. Music Therapy for People with Parkinson’s......Page 1299
64. Pathogenesis of Motor Response Complications in Parkinson’s Disease: “Mere Conjectural Suggestions” and Beyond......Page 1314
65. Treatment of Early Parkinson’s Disease......Page 1344
66. Moderate Parkinson’s Disease......Page 1362
67. Management of Advanced Parkinson’s Disease......Page 1374
68. Future Symptomatic Therapy in Parkinson’s Disease......Page 1396
69. Restorative Therapy in Parkinson’s Disease......Page 1411
70. Gene Therapy for Parkinson’s Disease......Page 1422
71. Translating Stem Cell Biology to Regenerative Medicine for Parkinson’s Disease......Page 1471
72. Alternative Drug Delivery in the Treatment of Parkinson’s Disease......Page 1505
73. The Role and Designs of Clinical Trials for Parkinson’s Disease......Page 1537
74. Positron Emission Tomography in Parkinson’s Disease......Page 1558
75. Economics of Parkinson’s Disease......Page 1579
76. Informal Caregivers: A Valuable Part of the Health Care Team......Page 1594
77. Quality of Life in Parkinson’s Disease: A Conceptual Model......Page 1609
78. The Evolution and Potential of the National Parkinson Organizations: A Brief Overview......Page 1620
Index......Page 1632